Kala Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
To access a live webcast and subsequent archived recording of the presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com
About
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFYTM mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYSTM for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease, for which a New Drug Application (NDA) has been filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005118/en/
Source:
Investors:
Michael Schaffzin, 212-362-1200
michael@sternir.com
or
Media:
Kari Watson, 781-235-3060
kwatson@macbiocom.com